Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer

Circulating endothelial cells (CECs) as well as bone-marrow-derived endothelial precursor cells (EPC) play an important role in neovascularisation and tumour growth. To study the impact of neoadjuvant chemotherapy on the amounts of CEC and their precursor cells, mature CEC and their progenitors were quantified by flow cytometry in peripheral blood of breast cancer patients during anthracycline and/or taxane based neoadjuvant chemotherapy and subsequent surgery in comparison to age-matched healthy controls. Cell numbers were tested for correlation with serum levels of angiopoietin-2, erythropoietin, endostatin, endoglin, VEGF and sVCAM-1 as well as clinical and pathological features of breast cancer disease. Circulating endothelial cells were significantly elevated in breast cancer patients and decreased during chemotherapy, whereas EPC (CD34+/VEGFR-2+) as well as their progenitor cell population CD133+/CD34+ and the population of CD34+ stem cells increased. Concomitantly with the increase of progenitor cells an increase of VEGF, erythropoietin and angiopoietin-2 was observed. These data suggest that chemotherapy can only reduce the amounts of mature CEC, probably reflecting detached cells from tumour vessels, whereas the EPC and their progenitors are mobilised by chemotherapy. Since this mobilisation of EPC may contribute to tumour neovascularisation an early antiangiogenic therapy in combination with chemotherapy could be beneficial for the success of cancer therapy.

[1]  L. Schwartzberg,et al.  Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. , 1992, Journal of hematotherapy.

[2]  D. Raoult,et al.  Demonstration of Rickettsia conorii-induced endothelial injury in vivo by measuring circulating endothelial cells, thrombomodulin, and von Willebrand factor in patients with Mediterranean spotted fever. , 1993, Blood.

[3]  H. Rochefort,et al.  Cathepsin D gene is controlled by a mixed promoter, and estrogens stimulate only TATA-dependent transcription in breast cancer cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Raoult,et al.  Demonstration of Rickettsia conorii-induced endothelial injury in vivo by measuring circulating endothelial cells, thrombomodulin, and von Willebrand factor in patients with Mediterranean spotted fever [see comments] , 1993 .

[5]  M. Kaufmann,et al.  Histologische Regression des Mammakarzinoms nach primärer (neoadjuvanter) Chemotherapie , 1994 .

[6]  H. Junkermann,et al.  [Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy]. , 1994, Geburtshilfe und Frauenheilkunde.

[7]  R. Law,et al.  Enhancement of radiosensitivity in human malignant glioma cells by hypericin in vitro. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  G. Viale,et al.  The microtubule-affecting drug paclitaxel has antiangiogenic activity. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  Takayuki Asahara,et al.  Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.

[10]  J. Isner,et al.  Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. , 1999, Circulation research.

[11]  J. Isner,et al.  VEGF contributes to postnatal neovascularization by mobilizing bone marrow‐derived endothelial progenitor cells , 1999, The EMBO journal.

[12]  A. Blann,et al.  HEMOSTASIS , THROMBOSIS , AND VASCULAR BIOLOGY Direct Evidence of Endothelial Injury in Acute Myocardial Infarction and Unstable Angina by Demonstration of Circulating Endothelial Cells , 1999 .

[13]  Haruchika Masuda,et al.  Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization , 1999, Nature Medicine.

[14]  U. Felbor,et al.  Generation and degradation of human endostatin proteins by various proteinases , 2000, FEBS letters.

[15]  H. Ploegh,et al.  Secreted cathepsin L generates endostatin from collagen XVIII , 2000, The EMBO journal.

[16]  S. Rafii,et al.  Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. , 2000, Blood.

[17]  J. Isner,et al.  Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[18]  S. Rafii,et al.  Circulating endothelial precursors: mystery, reality, and promise. , 2000, The Journal of clinical investigation.

[19]  R. Hebbel,et al.  Origins of circulating endothelial cells and endothelial outgrowth from blood. , 2000, The Journal of clinical investigation.

[20]  T. Murohara,et al.  Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. , 2000, The Journal of clinical investigation.

[21]  A. Nienhuis,et al.  Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  A. Goldhirsch,et al.  Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. , 2001, Blood.

[23]  Edward L Schwartz,et al.  Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. , 2002, Molecular cancer therapeutics.

[24]  F. Greene.  AJCC cancer staging handbook , 2002 .

[25]  Koichi Hattori,et al.  Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? , 2002, Nature Reviews Cancer.

[26]  S. Rafii,et al.  Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors , 2002, Gene Therapy.

[27]  L. Benjamin,et al.  Angiogenesis: Tumorigenesis and the angiogenic switch , 2003, Nature Reviews Cancer.

[28]  M. Hristov,et al.  Endothelial progenitor cells: mobilization, differentiation, and homing. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[29]  H. Lennernäs,et al.  Chemotherapy and Antiangiogenesis , 2003, Acta oncologica.

[30]  E. Voest,et al.  Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  Jian-hua Zhao,et al.  Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer. , 2004, Cancer letters.

[32]  D. Fliser,et al.  Erythropoietin regulates endothelial progenitor cells. , 2004, Blood.

[33]  D. Ribatti.  The involvement of endothelial progenitor cells in tumor angiogenesis , 2004, Journal of cellular and molecular medicine.

[34]  D. Sørensen,et al.  Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. , 2005, Blood.